ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer

Lin, Anqi; Yao, Jiarong; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*南方医科大学; 郑州大学; 1
Journal of Inflammation Research2023DOI: 10.2147/JIR.S394894
1被引13阅读
引用收藏
分享

摘要

Purpose: In recent years, tumour immunotherapy has ushered in a new era of oncology treatment. However, the use of immune checkpoint inhibitors (ICIs) in the treatment of CRC remains limited. There is an urgent clinical need for precise biomarkers that can aid in the screening and treatment of CRC subtypes. Therefore, we focused on the NOTCH pathway mutation status and conducted a systematic analysis for its predictive value of ICI therapy efficacy.Methods: We collected mutational and clinical data from cohorts of CRC patients treated with ICIs. The relationship between NOTCH pathway mutations (NOTCH-MT) and CRC immunotherapy prognosis was analysed using univariate and multivariate Cox regression models. CRC cohort data from The Cancer Genome Atlas (TCGA) database were combined to obtain a comprehensive overview of immunogenicity and tumour microenvironment (TME) differences among different NOTCH pathway mutation statuses.Results: We observed greater infiltration of M1 macrophages, CD8+ T cells, neutrophils, and activated natural killer (NK) cells with NOTCH-MT status. Immunogenicity was also significantly higher in patients with NOTCH-MT, as were tumour mutational burden (TMB), neoantigen load (NAL), and the number of mutations in DNA damage repair (DDR) pathways.Conclusion: NOTCH-MT status was strongly associated with the prognosis of CRC patients treated with ICIs and is expected to serve as a novel biomarker and therapeutic target for CRC.

学科与关键词

关键词
NOTCHCRCICIsbiomarkertumour microenvironment
相关
加载中…
  • Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer
    Wang, Fei; Huang, Chuan; Long, Jie; Zhao, Zhi-Bin; Ma, Hai-Qing*; Yao, Xue-Qing*; Li, Liang*; Lian, Zhe-XiongBMC CANCER, 2022, 22(1): 933.被引 8
  • Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
    Lin, Anqi; Xu, Wentao; Luo, Peng*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 721181.被引 5
  • Mutations in the notch signalling pathway are associated with enhanced anti-tumour immunity in colorectal cancer
    Wang, Fei; Long, Jie; Li, Liang; Zhao, Zhi-bin; Wei, Fang; Yao, Yuan; Qiu, Wen-Jing; Wu, Zi-Xin; Luo, Qing-Qing; Liu, Wei; Quan, Yi-Bo; Lian, Zhe-Xiong*; Cao, Jie*Journal of Cellular and Molecular Medicine, 2020, 24(20): 12176-12187.被引 16
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Inflammation Research
发表日期
2023
卷期
第 16 卷
页码
1693-1709
DOI
10.2147/JIR.S394894
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [2018A030313846, 2021A1515012593]; Science and Technology Planning Project of Guangdong Province [2019A030317020]; National Natural Science Foundation of China [81802257, 81871859, 81772457, 82172750, 82172811]

作者

  • L

    Lin, Anqi (第一作者)

    southern med univ

  • Y

    Yao, Jiarong

    southern med univ

查看全部 6 位作者收起作者
  • C

    Cheng, Quan

  • L

    Liu, Zaoqu

    1 · zhengzhou univ

  • L

    Luo, Peng (通讯)

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417